Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Cell Rep
; 21(11): 3298-3309, 2017 Dec 12.
Article
in En
| MEDLINE
| ID: mdl-29241554
ABSTRACT
Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient's living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Precision Medicine
/
Primary Cell Culture
/
Lung Neoplasms
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Language:
En
Journal:
Cell Rep
Year:
2017
Document type:
Article
Affiliation country:
United States